Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Temsirolimus |
Synonyms | |
Therapy Description |
Torisel (temsirolimus) binds to FKBP-12 and allosterically inhibits mTOR (PMID: 16883305). Torisel (temsirolimus) is FDA approved for advanced renal cell carcinoma (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Temsirolimus | Torisel | CCI-779 | mTORC1 Inhibitor 8 | Torisel (temsirolimus) binds to FKBP-12 and allosterically inhibits mTOR (PMID: 16883305). Torisel (temsirolimus) is FDA approved for advanced renal cell carcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | oral squamous cell carcinoma | not applicable | Temsirolimus | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Torisel (temsirolimus) inhibited proliferation and migration of oral squamous cell carcinoma cells in culture and suppressed tumor growth in cell line xenograft models of human oral squamous cell carcinoma (PMID: 20858724). | 20858724 |
FBXW7 R465H | lung adenocarcinoma | sensitive | Temsirolimus | Case Reports/Case Series | Actionable | In a clinical case study, a patient with lung adenocarcinoma harboring FBXW7 R465H demonstrated tumor shrinkage when treated with Torisel (temsirolimus) (PMID: 24360397). | 24360397 |
Unknown unknown | lung non-small cell carcinoma | not applicable | Temsirolimus | Phase I | Actionable | In a Phase I trial, Torisel (temsirolimus) in combination with radiation therapy demonstrated safety and efficacy in 5/8 NSCLC patients (PMID: 24373609). | 24373609 |
Unknown unknown | head and neck squamous cell carcinoma | not applicable | Temsirolimus | Phase II | Actionable | In a Phase II trial, treatment with Torisel (temsirolimus) resulted in disease stabilization in 57.6% (19/33) and tumor shrinkage in 39.4% (13/33) of patients with head and neck squamous cell carcinoma (PMID: 25527417). | 25527417 |
CTNNB1 mutant | endometrial cancer | predicted - sensitive | Temsirolimus | Phase II | Actionable | In a retrospective study of a Phase II trial, Torisel (temsirolimus) treatment resulted in an increased progression-free survival (HR 0.46) but not response rate (response difference 0.00) in advanced endometrial cancer patients harboring CTNNB1 mutations (PMID: 27016228). | 27016228 |
PIK3CA mutant | ovarian cancer | sensitive | Temsirolimus | Case Reports/Case Series | Actionable | In a clinical study, an ovarian cancer patient harboring a PIK3CA E542 mutation demonstrated stable disease when treated with Torisel (temsirolimus) (PMID: 21216929). | 21216929 |
PIK3CA mutant | ovarian cancer | sensitive | Temsirolimus | Phase I | Actionable | In a Phase I clinical trial, Torisel (temsirolimus) demonstrated limited efficacy in ovarian cancer patients with PIK3CA mutations (PMID: 22271473). | 22271473 |
PIK3CA H1047X | endometrial adenocarcinoma | predicted - sensitive | Temsirolimus | Case Reports/Case Series | Actionable | In a clinical study, a patient with endometrial adenocarcinoma harboring a PIK3CA H1047 mutation demonstrated a partial response when treated with Torisel (temsirolimus) (PMID: 21216929). | 21216929 |
PIK3CA mutant | breast cancer | no benefit | Temsirolimus | Phase II | Actionable | In a Phase II trial, Torisel (temsirolimus) treatment resulted in stable disease in 9.7% (3/31) of breast cancer patients positive for ER, PR or ERBB2 (HER2), however there was no association between PIK3CA mutational status and clinical benefits (PMID: 22245973). | 22245973 |
PIK3CA mutant | endometrial cancer | no benefit | Temsirolimus | Phase II | Actionable | In a retrospective study of a Phase II trial, mutation status of PIK3CA was not associated with progression-free survival or response rate in advanced endometrial cancer patients treated with Torisel (temsirolimus) (PMID: 27016228). | 27016228 |
AKT1 mutant | endometrial cancer | predicted - sensitive | Temsirolimus | Phase II | Actionable | In a retrospective study of a Phase II trial, Torisel (temsirolimus) treatment resulted in an increased progression-free survival (HR 0.16) and response rate (response difference 0.83) in advanced endometrial cancer patients harboring AKT1 mutations (PMID: 27016228). | 27016228 |
Unknown unknown | renal cell carcinoma | not applicable | Temsirolimus | FDA approved | Actionable | In a Phase III randomized trial that supported FDA approval, treatment with Torisel (temsirolimus) resulted in an improved overall survival time of 11.1 months in patients with advanced renal cell carcinoma compared to 7.4 months in patients treated with IFN-alpha (PMID: 20332142). | 20332142 detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01396408 | Phase II | Temsirolimus Sunitinib | A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours | Active, not recruiting | CAN | 0 |
NCT01517243 | Phase II | Temsirolimus Sunitinib | Phase II Study of Alternating Sunitinib and Temsirolimus | Active, not recruiting | USA | 0 |
NCT01087554 | Phase I | Temsirolimus Everolimus Sirolimus Vorinostat | Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer | Active, not recruiting | USA | 0 |
NCT02551718 | Phase I | Bosutinib Irinotecan Romidepsin Busulfan Melphalan Nilotinib Crizotinib Cytarabine Mitoxantrone Dasatinib Pazopanib Paclitaxel Clofarabine Hydroxyurea Tretinoin Carfilzomib Nelarabine Bexarotene Pentostatin Everolimus Cabozantinib Mercaptopurine Methotrexate Cladribine Thioguanine Daunorubicin Ponatinib Etoposide Afatinib Gefitinib Gemcitabine Regorafenib Arsenic trioxide Trametinib Imatinib Erlotinib Dabrafenib Decitabine Axitinib Azacitidine Ruxolitinib Fludarabine Lapatinib Ceritinib Sirolimus Sorafenib Lomustine Sunitinib Cabazitaxel Temsirolimus Topotecan Bortezomib Pralatrexate | High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia | Active, not recruiting | USA | 0 |
NCT01614197 | Phase I | Etoposide Cyclophosphamide Prednisone Cytarabine Temsirolimus Methotrexate | A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma | Completed | USA | CAN | 1 |
NCT01767194 | Phase II | Dinutuximab Temsirolimus Irinotecan + Temozolomide | Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma | Completed | USA | CAN | 3 |
NCT03297606 | Phase II | Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) | Recruiting | CAN | 0 |
NCT02567435 | Phase III | Cyclophosphamide + Dactinomycin + Vincristine Sulfate Temsirolimus Irinotecan | Combination Chemotherapy and Irinotecan Hydrochloride or Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma | Recruiting | USA | CAN | 3 |
NCT02420613 | Phase I | Vorinostat Temsirolimus | Study of Suberoylanilide Hydroxamic Acid (SAHA) With Temsirolimus in Children With Diffuse Intrinsic Pontine Glioma (DIPG) | Active, not recruiting | USA | 0 |
NCT04199026 | Phase I | Irinotecan Doxorubicin Ifosfamide Temozolomide Temsirolimus Ganitumab Pazopanib Everolimus Vincristine Sulfate | Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma | Not yet recruiting | USA | 0 |
NCT01180049 | FDA approved | Temsirolimus | Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma | Completed | USA | 10 |
NCT01187199 | Phase I | Bevacizumab Paclitaxel Carboplatin Sorafenib Temsirolimus | Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer | Active, not recruiting | USA | 0 |
NCT01567930 | Phase II | Temsirolimus | Temsirolimus as Second-line Therapy in HCC | Unknown status | USA | 0 |
NCT02446431 | Phase I | Cyclophosphamide Bevacizumab Temsirolimus Valproic acid | Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence | Recruiting | USA | 0 |
NCT02560012 | Phase II | Everolimus Sorafenib Temsirolimus Axitinib Sunitinib Pazopanib | Personalized Targeted Inhibitors Treatment in Renal Cell Cancer | Terminated | USA | 0 |
NCT02423954 | Phase Ib/II | Temsirolimus Nivolumab Capecitabine Irinotecan | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) | Terminated | USA | 0 |
NCT01392183 | Phase II | Diphenhydramine Temsirolimus Pazopanib | Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) | Completed | USA | 0 |
NCT02693535 | Phase II | Cobimetinib + Vemurafenib Regorafenib Ipilimumab + Nivolumab Palbociclib Afatinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Crizotinib Abemaciclib Sunitinib Olaparib | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | Recruiting | USA | 0 |
NCT00838955 | Phase II | Temsirolimus | Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma | Terminated | USA | 0 |
NCT02788201 | Phase II | Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | Completed | USA | 0 |